Equities

Corcept Therapeutics Inc

Corcept Therapeutics Inc

Actions
  • Price (EUR)54.82
  • Today's Change-0.32 / -0.58%
  • Shares traded10.00
  • 1 Year change+134.27%
  • Beta--
Data delayed at least 15 minutes, as of Nov 13 2024 07:04 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments368432224
Total Receivables, Net413128
Total Inventory7.736.104.99
Prepaid expenses281610
Other current assets, total1414--
Total current assets459499266
Property, plant & equipment, net0.321.781.52
Goodwill, net------
Intangibles, net------
Long term investments574.95112
Note receivable - long term------
Other long term assets151616
Total assets622583424
LIABILITIES
Accounts payable17126.91
Accrued expenses856040
Notes payable/short-term debt000
Current portion long-term debt/capital leases------
Other current liabilities, total1.810.090.51
Total current liabilities1057248
Total long term debt000
Total debt000
Deferred income tax------
Minority interest------
Other liabilities, total109.100.41
Total liabilities1158248
SHAREHOLDERS EQUITY
Common stock0.130.130.13
Additional paid-in capital739662591
Retained earnings (accumulated deficit)403296195
Treasury stock - common(635)(456)(410)
Unrealized gain (loss)------
Other equity, total0.61(0.87)(0.23)
Total equity507502376
Total liabilities & shareholders' equity622583424
Total common shares outstanding103131106
Treasury shares - common primary issue312321
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.